As been explained multiple times. The amount of shorts (60+ Million for over a year 30% of float) confounds almost anyone who knows the company, cash position, market share and market size. Anybody short this stock under $14.00 yes I said $14.00 is playing chicken with the devil. If not a major new market, or a buyout, the sales themselves can make this a $20 stock on a press release. They got bigger drugs than Belviq ready for trials.
I love the old "My IP is cloaked and nobody can locate me" joke" The feds can find a15 year old XP unit on a phone modem. Everything your cloaked system plugs into ... has a MAC address that leads back to the source.
We know you went to school for the money. You never saw a real patient (ever) and used your credentials as a way to influence pharma investors. We can also see to it that those credentials disappear as fast as you can write another false downgrade. One letter to the right board starts the process. You know the consequences of unapproved use of medical certifications. Wise up, you're not above the law or bio ethics.
You cant fake doctors out about safety. You cant sell products that are not approved. You cant attract patient users without advertising.. Qysmia and Conrave are hedge funds scam fronts and nothing more. Anyone on the clinician side knows it. Ask them.
Ask them for clarification about the "safety issues" Simone was talking about. A few years with Bernie could help him focus more.
Is the best buy sign you're ever going to see
Arena retail don't use stops or loan shares. BUT the funds who hold the minority shares liberally loaned them out to short sellers and option parlors in an ongoing attempt to wrest majority interest before Belviq hits the big numbers.
Arena is not DNDN, its the safest retail drug for obesity and is still on the launch pad
Sentiment: Strong Buy
GREAT CALL DUDE
Credit Suisse Can't Nix Prudential's $460M RMBS Suit
Law360, New York (October 01, 2013, 7:47 PM ET) -- A New Jersey federal judge refused Monday to toss Prudential Insurance Co. of America's $460 million fraud and racketeering suit against Credit Suisse AG, saying Prudential's complaint contained sufficient detail to advance fraud claims under New Jersey law.
In a case originally brought against Credit Suisse and several of its affiliates in New Jersey federal court in August 2012, Prudential accuses Credit Suisse of fraud, misrepresentation and violation of New Jersey's racketeering laws
He just made a hedge fund plus his closest friends and family a bundle. In a month He will revise his forecast and hump u again. People in NY will be watching him like a movie and this ones wont have a good ending,
A downgrade on the eve of a federal shut down is as good as any short will ever get.
Thanks, I added enough to put a new Porsche on the road by April.
Thats TWO down days in a row,, more buyers , positive cash
You will find no better bullish indicator.